ReviewStroke2026
Neural Repair Therapies After Stroke: I. Therapeutic Advances.
Review in Stroke, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Stroke is a leading cause of disability worldwide. Neural repair therapies, distinct from acute stroke therapies, target surviving neural elements to promote plasticity after the acute injury has occurred. Repair therapies encompass a broad and rapidly evolving therapeutic landscape, ranging from behavioral training, drugs, and biological agents to neural stimulation. In this review, we highlight major advances across these therapeutic categories, focusing on the evidence base and readiness for clinical adoption. Intensive behavioral interventions, including constraint-induced movement therapy and telerehabilitation, result in meaningful gains even in chronic stroke. Biological therapies-growth factors, monoclonal antibodies, and stem cell approaches-show promise but face translational challenges. Pharmacological strategies targeting serotonergic and dopaminergic systems have yielded mixed results. Neural stimulation approaches span a spectrum of invasiveness, with vagus nerve stimulation now Food and Drug Administration-approved and emerging candidates including cerebellar deep brain stimulation and spinal cord epidural stimulation showing early promise. These studies have provided important lessons for neural repair trial design. Synthesizing evidence across modalities, we highlight how therapeutic advances are reshaping the landscape of poststroke recovery and identify the most promising opportunities for clinical translation. Emerging neural repair strategies stand to substantially improve function after stroke.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.